Macrophage TRPML1 ameliorates post-myocardial infarction inflammation by blocking VDAC1 oligomerization to prevent ferroptosis and cGAS-STING activation

  • Free Radic Biol Med. 2026 Aug 16:252:166-183. doi: 10.1016/j.freeradbiomed.2026.05.006.
Xiuye Zhao  1 Jia Wang  1 Zhenru Wang  1 Haonan Du  1 Hongda Li  1 Tong Wu  1 Kaixuan Yang  1 Linshan Xie  1 Mingxiu Zhang  1 Jiapan Wang  1 Peifeng Li  1 Changling Lv  1 Yushu Deng  1 Hongyu Ji  1 Yan Zhang  1 Xingda Li  1 Ye Yuan  2 Zhimin Du  3
Affiliations
  • 1. Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (National Key Laboratory of Frigid Cardiovascular Disease), Harbin, 150081, China.
  • 2. Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (National Key Laboratory of Frigid Cardiovascular Disease), Harbin, 150081, China. Electronic address: [email protected].
  • 3. Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (National Key Laboratory of Frigid Cardiovascular Disease), Harbin, 150081, China; State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, 999078, Macau. Electronic address: [email protected].
Abstract

Precise modulation of the inflammatory response is critical for clearing damaged cardiomyocytes and promoting tissue regeneration after myocardial infarction (MI). Transient receptor potential mucolipin 1 (TRPML1) is an endo/lysosomal cation channel involved in regulating lysosomal biogenesis, Fe2+ homeostasis, and phagocytic function; however, its role in post-MI inflammation remains unclear. This study shows that TRPML1 was significantly downregulated at both the protein and transcriptional levels in mouse cardiac tissue on days 3 and 7 post-MI. Using genetic lineage tracing, we found that macrophage-specific overexpression of TRPML1 attenuated the M1-dominant inflammatory response while enhancing M2-mediated repair in the infarcted area, ultimately reducing infarct size and improving cardiac function. In vitro co-culture experiments further demonstrated that activating macrophage TRPML1 restored the viability and Collagen synthesis capacity of cardiac fibroblasts impaired by lipopolysaccharide (LPS). Mechanistically, TRPML1 directly targets Voltage-Dependent Anion Channel 1 (VDAC1) and inhibits its oligomerization, thereby reducing oxidative stress and Ferroptosis in macrophages, and blocking mitochondrial DNA (mtDNA) escape into the cytoplasm and the subsequent activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. This inhibition significantly alleviated the downstream pro-inflammatory cytokine storm. Importantly, inhibition of VDAC1 oligomerization with NSC 15364 rescued the Ferroptosis and cardiac inflammation phenotypes in macrophage-specific TRPML1 knockout (Mac-TRPML1 KO) mice post-MI. In summary, our study identifies macrophage TRPML1 as a key metabolic checkpoint that regulates post-MI repair by controlling macrophage Ferroptosis and cardiac fibroblast activation. We propose that targeting the TRPML1-VDAC1-cGAS-STING signaling axis may serve as a novel therapeutic strategy for post-MI inflammation.

Keywords
Ferroptosis; Inflammation; Myocardial infarction; TRPML1; VDAC1 oligomerization; cGAS-STING.
Products
Inhibitors & Agonists